IFIH1 and juvenile dermatomyositis: To evaluate the effectiveness and safety of multitarget therapy in patients with anti-MDA5 antibody-positive DM and JDM without the use of CY, we conducted a comprehensive literature review (Figure 3; PRISMA diagram).